Home

krom Gorgelen succes 5 year overall survival navigatie Hopelijk knoop

Overall Survival After 5 Years in Patients With Locally Advanced SCCHN  Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT |  PracticeUpdate
Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate

Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival  Prediction for Stage II–III Rectal Cancer
Frontiers | Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II–III Rectal Cancer

Overall survival curve by treatment method. The 5-year overall survival...  | Download Scientific Diagram
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram

Real-world treatment and survival of patients with advanced non-small cell  lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text

This figure shows the 5-year overall survival (OS) in 250 synovial... |  Download Scientific Diagram
This figure shows the 5-year overall survival (OS) in 250 synovial... | Download Scientific Diagram

5-year overall survival almost doubled with pembrolizumab for metastatic  NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations -  BJMO
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO

Efficacy Results | Myelofibrosis Clinical Trials | Jakafi HCP
Efficacy Results | Myelofibrosis Clinical Trials | Jakafi HCP

Significant 5-year overall survival following neoadjuvant nivolumab in lung  cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe
Significant 5-year overall survival following neoadjuvant nivolumab in lung cancer - Hospital Pharmacy EuropeHospital Pharmacy Europe

A, Kaplan-Meier curve of 5-year overall survival (OS) and 5-year... |  Download Scientific Diagram
A, Kaplan-Meier curve of 5-year overall survival (OS) and 5-year... | Download Scientific Diagram

Stereotactic ablative radiotherapy shows long-term benefit in operable  early NSCLC
Stereotactic ablative radiotherapy shows long-term benefit in operable early NSCLC

Mammography correlates to better survival rates in breast cancer patients:  a 20-year experience in a University health institution - ecancer
Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution - ecancer

Prognosis and survival analysis of patients with pancreatic cancer:  retrospective experience of a single institution | World Journal of  Surgical Oncology | Full Text
Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution | World Journal of Surgical Oncology | Full Text

Acute lymphoblastic leukemia: A population‐based study of outcome in the  United States based on the surveillance, epidemiology, and end results  (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology  - Wiley Online Library
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 - Sasaki - 2021 - American Journal of Hematology - Wiley Online Library

Study shows survival benefits of smoking cessation after lung cancer  diagnosis
Study shows survival benefits of smoking cessation after lung cancer diagnosis

Assessment of 5-year overall survival in bladder cancer patients with  incidental prostate cancer identified at radical cystoprostatectomy |  SpringerLink
Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy | SpringerLink

Survival Stats for Pancreas Cancer
Survival Stats for Pancreas Cancer

Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage  III NSCLC
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC

Five-year survival analysis of surgically resected gastric cancer cases in  Japan: a retrospective analysis of more than 100,000 patients from the  nationwide registry of the Japanese Gastric Cancer Association (2001–2007)  | SpringerLink
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink

Kaplan-Meier survival curves comparing 5-year overall survival (OS) and...  | Download Scientific Diagram
Kaplan-Meier survival curves comparing 5-year overall survival (OS) and... | Download Scientific Diagram

survival - 5-year EFS > 5-year OS - Cross Validated
survival - 5-year EFS > 5-year OS - Cross Validated

5-year overall survival in patients with lung cancer eligible or ineligible  for screening according to US Preventive Services Task Force criteria: a  prospective, observational cohort study - The Lancet Oncology
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology

4baseCare on Twitter: "Research data suggests that 5-year survival rates in  different subtypes of Cholangiocarcinoma vary in different stages of the  disease. LINK: https://t.co/yh5Cbkcr1j #MedTwitter https://t.co/nhmwIeZAg9"  / Twitter
4baseCare on Twitter: "Research data suggests that 5-year survival rates in different subtypes of Cholangiocarcinoma vary in different stages of the disease. LINK: https://t.co/yh5Cbkcr1j #MedTwitter https://t.co/nhmwIeZAg9" / Twitter

Predictive model for the 5-year survival status of osteosarcoma patients  based on the SEER database and XGBoost algorithm | Scientific Reports
Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports

Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC  Patients With Synchronous Oligometastases Treated in a Prospective Phase II  Trial (NCT 01282450) - ScienceDirect
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect

Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer  over Five Decades
Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades